In this issue:
HTX and m-EASIX risk scores may improve pre-bispecific risk stratification
Bridging to teclistamab with debulking chemotherapy overcomes primary resistance
Low-dose tocilizumab prophylaxis mitigates bispecific-associated CRS
Bispecific + pomalidomide is an effective salvage for relapse after T-cell redirection therapy
PROs comparable or better with elranatamab in triple-class refractory MM
Dismal prognosis for patients with CNS involvement
PCd is effective for double- and triple-refractory RRMM
CSF-1R inhibition + lenalidomide maintenance may overcome post-transplant immune escape
PET/CT derived mTMTV is a novel prognostic biomarker for newly diagnosed MM
Expert insights on treatment selection for MM at first relapse
Please login below to download this issue (PDF)